Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

MedStar author(s):
Citation: European Journal of Heart Failure. 22(11):1945-1960, 2020 11.PMID: 32463967Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov'tSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2020ISSN:
  • 1388-9842
Name of journal: European journal of heart failureAbstract: This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. Copyright (c) 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.All authors: Andres MS, Anker MS, Barac A, Bauersachs J, Belenkov Y, Bergler-Klein J, Brezden-Masley C, Cardinale D, Chioncel O, Ciardiello F, Coats AJS, Cohen-Solal A, Cornell RF, de Boer RA, de Lavallade H, Dent S, Earl H, Farmakis D, Fradley MG, Groarke JD, Hajjar LA, Herrmann J, Iakobishvili Z, Khoo V, Ky B, Lenihan D, Lopez-Fernandez T, Lyon AR, Maack C, Macedo AVS, Manisty C, Mauro MJ, Milojkovic D, Moslehi JJ, Neilan TG, Plummer C, Pudil R, Rosen SD, Ruschitzka F, Seferovic PM, Skouri H, Stanway S, Suter TM, Sverdlov AL, Tan LL, Thavendiranathan P, Thum T, Tocchetti CG, von Haehling S, Wechelaker A, Witteles RM, Wright DJFiscal year: FY2021Digital Object Identifier: Date added to catalog: 2020-08-26
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32463967 Available 32463967

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. Copyright (c) 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

English

Powered by Koha